Physician profile
Christopher Caggiano
NPI 1447241443
$27,566.45
in general payments reported to CMS, 2019-2025
59 companies · $3,442 in 2025
The $3,442 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,466 · 2020: $3,366 · 2021: $3,922 · 2022: $3,360 · 2023: $4,273 · 2024: $3,737 · 2025: $3,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Education: $60.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,191.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Education | $60.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,115.80 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $3,502.20 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $2,688.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,973.46 | 2019-2025 | Jardiance, Synjardy |
| Biotronik INC. | $1,932.62 | 2019-2020 | |
| Pfizer INC. | $1,805.90 | 2019-2025 | |
| Lilly USA, LLC | $1,174.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $840.87 | 2019-2023 | |
| Amgen INC. | $819.68 | 2019-2025 | Evenity, Repatha, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $793.74 | 2021-2025 | |
| Abbott Laboratories | $750.28 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $691.54 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $480.17 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $465.12 | 2019-2025 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $439.37 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Caggiano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.